445306-08-1

Basic information

• Product Name: (2S,4R)-1-((S)-2-tert-butoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid
• Synonyms: (2S,4R)-1-((S)-2-tert-butoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid
• CAS NO: 445306-08-1
• Molecular Weight: 577.678
• Mol File: 445306-08-1.mol

Chemical Properties

• CAS DataBase Reference: (2S,4R)-1-((S)-2-tert-butoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,4R)-1-((S)-2-tert-butoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid(445306-08-1)
• EPA Substance Registry System: (2S,4R)-1-((S)-2-tert-butoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid(445306-08-1)

Safety Data

• Hazardous Substances Data: 445306-08-1(Hazardous Substances Data)

Upstream product

• 445306-09-2 (2S,4R)-1-((S)-2-tert-butoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid methyl ester 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 20430-72-2 7-methoxy-2-phenylquinolin-4-ol 
• 74844-91-0 (2S,4S)-N-tert-butoxycarbonyl-4-hydroxyproline methyl ester 
• 737750-26-4 (2S,4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carboxylic acid methyl ester 
• 259214-70-5 (2S,4R)-4-(7-Methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-methyl ester 

Downstream Products

• 681809-03-0 C₃₇H₄₆N₄O₈ 
• 1131985-40-4 C₄₁H₄₈N₄O₈ 
• 1028412-38-5 C₃₉H₄₂BrF₃N₄O₆ 
• 1131987-44-4 C₄₁H₄₈N₄O₈ 
• 1028412-36-3 C₃₉H₄₅BrN₄O₆ 
• 1131984-66-1 C₄₀H₄₆N₄O₈ 
• 1028412-13-6 C₃₈H₄₃BrN₄O₆ 
• 1028412-15-8 C₃₈H₄₃BrN₄O₆ 
• 1028412-11-4 C₃₈H₄₃BrN₄O₆ 
• 1131986-12-3 C₄₀H₄₆N₄O₈ 
• 259216-88-1 (1R,2S)-1-{[(2S,4R)-1-((S)-2-tert-butoxycarbonylamino-3,3-dimethyl-butyryl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-pyrrolidine-2-carbonyl]-amino}-2-vinyl-cyclopropanecarboxylic acid 

Relevant articles and documents

A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: Discovery of potent and specific tripeptide inhibitors

The inadequate efficacy and tolerability of current therapies for the infectious liver disease caused by the hepatitis C virus have warranted significant efforts in the development of new therapeutics. We have previously reported competitive peptide inhib

Substituted cycloalkyl P1' hepatitis C virus inhibitors

The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.